SBIR/STTR Research Award

Ex Vivo Culture of Umbilical Cord Blood Stem Cells for Adult Transplantation

Award identifier a6eec1dd10000d4bc8e5ced09eb2315626f8ac9f38a79eb3580e40bf6c1f49afAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$818,915

Program and phase

SBIR · Phase II

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
QUALITY BIOLOGICAL, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
V7ACWSNAL845
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The overall goal of this proposal is to delineate the ex vivo serum-free culture conditions to expand CD34+ cells derived from cryopreserved umbilical cord blood cells to levels that will support its use in the adult transplant setting. The disadvantage of umbilical cord blood for adult transplants has been attributed to having too few long-term engrafting cells/hematopoietic stem cells in the cord blood. Studies presented herein suggest that this problem can be circumvented based on 1) the development of a clinical grade serum-free medium designated especially for the ex vivo expansion of CD 34+ cells derived from cord blood, 2) the successful expansion of CD 34+ cells from cryopreserved umbilical cord blood to levels adequate to support adult transplantation using the clinical grade serum-free medium with the early acting cytokines, Flt-3 ligand, stem cell factor, thrombopoietin, and Interleukin 6, and 3) the ability of these ex vivo cultured CD 34+ cells to engraft long-term in the fetal sheep model for human hematopoiesis. The Phase I milestone will be to repeat and extended these initial studies and assess the long-term engrafting ability of these cultured CD 34+ cells in increased numbers of animals and evaluate longer culture periods. These critical results will form the basis of the Phase II proposal to determine if 1) the long-term engrafting cells are being expanded or maintained under these ex vivo serum-free culture conditions, 2) define the optimal culture period yielding high quality long-term engrafting cells, and 3) evaluate other cytokines in combination with the above cytokine platform. The ability to expand the long-term engrafting cells would be invaluable in the adult transplant setting. The efforts from this proposal will yield clinically relevant data on the optimal conditions necessary for use of cryopreserved cord blood for adult transplantation. . The products derived form this proposal will support the ex vivo culture of CD34+ cells derived from cryopreserved umbilical cord blood and the maintenance of these cells ability to engraft long-term. Since cord blood has few long-term engrafting cells /hematopoietic stem cells it can only be used for infant transplantation, not adult transplantation. The ability to develop a serum-free clinical grade culture system that will support the expansion of the long-term engrafting cells will facilitate the clinical use of these cells in adult transplants.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

25 SBIR/STTR records share this UEI (1987–2020). Reported award amounts total $6,768,750. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.